I too am in agreement with those who say the timelines are out of our control. I firmly believe we're at the mercy of Sheba or whomever is conducting Phase II. Research hospitals do hundreds of studies yearly and we have to fit their schedule, not ours. That being said I'm disappointed that the announcement of the successful completion of Phase I had no effect on investor sentiment. I honestly felt it should have given us new legitimacy and a higher pps. At this point I think a letter from Dr. Hirsch is warranted explaining the process and why these delays happen. We have made real progress by completing the first ever IRB approved safety study for cannabis based medicine. I wish the company's PR had been worded a little differently to reflect that reality.